Current Report · Items 8.01, 9.01 · 8-K
Traws Pharma, Inc.
TRAWNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. As previously disclosed in that Current Report on Form 8-K filed by Traws Pharma, Inc. (the “Company”) with the Securities and Exhange Commission (the “Commission”) on March 10, 2025, on March 10, 2025, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with Citizens JMP Securities, LLC (“Citizens”), pursuant to which the Company may offer an…
Filed Jul 10, 2026Accepted Jul 10, 2026, 4:02 PM EDTCIK 1130598Accession 0001104659-26-082649
Company context
Pharma, Inc. Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health including seasonal influenza and H5N1 bird flu, negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, Lassa Fever and COVID-19/Long COVID.
Current securities
Historical securities (2)
Disclosure sections
Items 8.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
As previously disclosed
in that Current Report on Form 8-K filed by Traws Pharma, Inc. (the “Company”) with the Securities and Exhange Commission
(the “Commission”) on March 10, 2025, on March 10, 2025, the Company entered into an At The Market Offering Agreement
(the “ATM Agreement”) with Citizens JMP Securities, LLC (“Citizens”), pursuant to which the Company may offer
and sell shares of its common stock, having aggregate sales price of up to $50,000,000 (subject to certain limitations set forth in the
ATM Agreement), from time to time, to or through Citizens, acting as sales agent and/or principal. The shares of Company common stock
will be sold pursuant to the Company’s effective shelf registration statement on Form S-3 and an accompanying prospectus
(Registration Statement No. 333-297195), filed with the Commission on July 1. 2026, and declared effective by the
Commission on July 9, 2026, including the base prospectus contained therein, as supplemented by that prospectus supplement dated
July 10, 2026 (the “Prospectus Supplement”), and filed with the Commission pursuant to Rule 424(b) under the
Securities Act of 1933, as amended. In accordance with the terms of the ATM Agreement, under the Prospectus Supplement, the Company may
offer and sell shares of its common stock (the “Shares”) having an aggregate offering price of up to $5,575,709, from time
to time, to our through Citizens, which is the Company’s current “baby shelf” limitation under General Instruction I.B.6.
of Form S-3.
A copy of the legal opinion
of Snell & Wilmer L.L.P. relating to the Shares to be sold under the ATM Agreement is filed as Exhibit 5.1 to this Current
Report and incorporated herein by reference.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
──────────────────────────────────────────────────────────────────────────────────────────
5.1 Opinion
of Snell & Wilmer L.L.P.
23.1 Consent
of Snell & Wilmer L.L.P. (included in Exhibit 5.1).
104 Cover
Page Interactive Data File (embedded within the inline XBRL Document)